Consensus Danaher Corporation

Equities

DHR

US2358511028

Real-time Estimate Cboe BZX Other stock markets 01:48:49 2024-09-13 pm EDT			5-day change	1st Jan Change
274.34 ^USD	+0.68%		+2.87%	+18.37%

12:06pm	RBC Raises Price Target on Danaher to $333 From $300, Keeps Outperform Rating	MT
Sep. 11	Analyst recommendations: Exxon Mobil, Accenture, Citigroup, Morgan Stanley...

Evolution of the Average Target: Danaher Corporation

Evolution of the Target Price: Danaher Corporation

Changes in Analyst Recommendations: Danaher Corporation

20c5c6da88289e1fd150c1f4fd7125.3X8Ohzn3rfUKR54eCMa3TqsuYWygPj_ZBLuBmT4OWMs.m0Zvt3eByrZpPqwrTovGK-F0G1zsXW-XQvXx0lBnHKzwJX3KXKX6gVsC6Q~1c63095d0f3d11a33a58d3b74477acaa

Analysts' recommendations: Danaher Corporation

RBC Raises Price Target on Danaher to $333 From $300, Keeps Outperform Rating	06:06am	MT
Analyst recommendations: Exxon Mobil, Accenture, Citigroup, Morgan Stanley...	Sep. 11
Deutsche Bank Raises Price Target on Danaher to $285 From $270	Sep. 11	MT
Wells Fargo Initiates Danaher at Equalweight With $280 Price Target	Aug. 28	MT
Redburn Atlantic Adjusts Price Target on Danaher to $280 From $260	Jul. 25	MT
TD Cowen Adjusts Price Target on Danaher to $310 From $290	Jul. 24	MT
HSBC Adjusts Price Target on Danaher to $300 From $290	Jul. 24	MT
Baird Adjusts Price Target on Danaher to $278 From $275	Jul. 24	MT
Leerink Adjusts Price Target on Danaher to $280 From $275	Jul. 24	MT
Barclays Adjusts Price Target on Danaher to $285 From $270	Jul. 24	MT
Raymond James Adjusts Price Target on Danaher to $310 From $285	Jul. 24	MT
Stifel Adjusts Price Target on Danaher to $250 From $235	Jul. 24	MT
Citigroup Adjusts Price Target on Danaher to $305 From $290	Jul. 24	MT
JPMorgan Adjusts Price Target on Danaher to $305 From $295	Jul. 24	MT
RBC Raises Price Target on Danaher to $300 From $297, Keeps Outperform Rating	Jul. 24	MT
Goldman Sachs Raises Danaher's Price Target to $250 From $225	Jul. 23	MT
Evercore ISI Adjusts Price Target on Danaher to $275 From $260, Maintains Outperform Rating	Jul. 23	MT
JPMorgan Adjusts Price Target on Danaher to $295 From $300	Jul. 18	MT
Goldman Sachs Adjusts Price Target on Danaher to $225 From $220, Maintains Neutral Rating	Jul. 08	MT
Evercore ISI Cuts Price Target on Danaher to $260 From $266, Maintains Outperform Rating	Jul. 02	MT
Danaher Insider Sold Shares Worth $4,866,675, According to a Recent SEC Filing	May. 15	MT
Danaher Insider Sold Shares Worth $11,735,856, According to a Recent SEC Filing	May. 13	MT
Raymond James Adjusts Price Target on Danaher to $285 From $270, Keeps Outperform Rating	Apr. 29	MT
Danaher Insider Sold Shares Worth $5,618,569, According to a Recent SEC Filing	Apr. 26	MT
Danaher Insider Sold Shares Worth $11,756,725, According to a Recent SEC Filing	Apr. 25	MT

More recommendations

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analyst Opinion	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	DANAHER CORPORATION					+5.16%
	THERMO FISHER SCIENTIFIC INC.					+2.98%
	INTUITIVE SURGICAL, INC.					-2.04%
	BOSTON SCIENTIFIC CORPORATION					+4.09%
	SIEMENS HEALTHINEERS AG					+18.73%
	EDWARDS LIFESCIENCES CORPORATION					+16.57%
	SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.					+57.63%
	AGILENT TECHNOLOGIES, INC.					+8.15%
	GE HEALTHCARE TECHNOLOGIES INC.					+8.58%
	RESMED, INC.					-7.27%
	Average					+11.26%
	Weighted average by Cap.					+6.44%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

272.49USD

Average target price

286.55USD

Spread / Average Target

+5.16%

High Price Target

310.00USD

Spread / Highest target

+13.77%

Low Price Target

250.00USD

Spread / Lowest Target

-8.25%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Deutsche Bank Securities
Raymond James
HSBC
TD Cowen
Barclays
Citigroup
Baird
Leerink Partners
RBC Capital Markets
Goldman Sachs
Evercore ISI
KeyBanc Capital Markets
UBS
BofA Securities
Morningstar
Wells Fargo Securities
Jefferies & Co.
SVB Securities LLC
Nephron Research
JPMorgan Chase
Stifel Nicolaus
Credit Suisse
Cowen
Benchmark Company
Bernstein
B. Riley
Benchmark Capital